Abstract: Chronic hepatitis B is one of the most common chronic infectious diseases in China. The
proportion of HBeAg-negative chronic hepatitis B which do harm to the security of public health in China has
been rising year by year. In recent years, some domestic and foreign guidelines advised that the end point of
therapy for HBeAg-negative chronic hepatitis B should be the HBsAg loss. However, it is hard to achieve by
pegylated interferon or nucleos(t)ide analogue. This article reviewed the present status of antiviral therapy for
HBeAg negative chronic hepatitis B and the progress of optimal treatment strategies to achieve HBsAg loss.